Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL711976

CCCCCCn1cc[n+](C)c1C.O=S(=O)([O-])C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 7/20 0.47
EEF2K O00418 2/20 0.43
EEF2 P13639 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PLK4 O00444 1/20 0.43
JAK2 O60674 1/20 0.43
EGFR P00533 1/20 0.43
TYK2 P29597 1/20 0.43
FLT3 P36888 1/20 0.43
BLM P54132 1/20 0.43
ITK Q08881 1/20 0.43
PIM2 Q9P1W9 1/20 0.43
CA1 P00915 5/20 0.41
CA2 P00918 5/20 0.41
APAF1 O14727 1/20 0.36
NPC1 O15118 1/20 0.36
PLA2G1B P04054 1/20 0.36
HSP90AA1 P07900 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL1329123 1.00 KCNH2 (0.47) KCNH2EEF2KEEF2MEN1KMT2A
Trifluoromethanesulfonic Acid SCHEMBL1329988 1.00 KCNH2 (0.47) KCNH2EEF2KEEF2MEN1KMT2A
Trifluoromethanesulfonic Acid SCHEMBL1330199 1.00 KCNH2 (0.47) KCNH2EEF2KEEF2MEN1KMT2A
Trifluoromethanesulfonic Acid SCHEMBL707414 0.95 KCNH2 (0.43) KCNH2EEF2KEEF2MEN1KMT2A
Trifluoromethanesulfonic Acid SCHEMBL1681503 0.89 KCNH2 (0.39) KCNH2CA1CA2HTTSMN1; SMN2
SCHEMBL29409279 0.87 MEN1 (0.41) KCNH2EEF2KEEF2MEN1KMT2A
SCHEMBL31030088 0.87 MEN1 (0.41) KCNH2EEF2KEEF2MEN1KMT2A
SCHEMBL29800177 0.87 MEN1 (0.41) KCNH2EEF2KEEF2MEN1KMT2A
SCHEMBL23004261 0.85 MEN1 (0.44) KCNH2EEF2KEEF2MEN1KMT2A
Trifluoromethanesulfonic Acid SCHEMBL1330268 0.84 ACHE (0.40) KCNH2MAPTHTTSMN1; SMN2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY INC (US) 2021-12-23 US claimed
US-20130341561-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY, INC. (US) 2013-12-26 US claimed
US-7718579-B2 Electrochemical deblocking using a hydrazine derivative COMBIMATRIX CORPORATION (US) 2010-05-18 US claimed
EP-1869061-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY Combimatrix Corporation (US) 2007-12-26 EP claimed
EP-1805206-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE Combimatrix Corporation (US) 2007-07-11 EP claimed
US-20070034513-A1 Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array COMBIMATRIX CORPORATION 2007-02-15 US claimed
WO-2007006418-A1 IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2007-01-18 WO claimed
WO-2006131234-A1 COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2006-12-14 WO claimed
WO-2006105037-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY COMBIMATRIX CORPORATION (US) 2006-10-05 WO claimed
WO-2006031814-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE COMBIMATRIX CORPORATION (US) 2006-03-23 WO claimed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 US claimed
US-20240101999-A1 HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS THERMO FISHER SCIENTIFIC GENEART GMBH (DE) 2024-03-28 US disclosed
CN-115927293-A Efficient small volume nucleic acid synthesis 生命技术公司 2023-04-07 CN disclosed
CN-107532129-B Efficient small volume nucleic acid synthesis 生命技术公司 2022-09-13 CN disclosed
EP-3557262-B1 HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS LIFE TECHNOLOGIES CORP (US) 2022-08-10 EP disclosed
US-20060192819-A1 Recording apparatus FUJI XEROX CO., LTD. 2006-08-31 US disclosed
EP-1695829-A2 Recording apparatus with ionic ink or ionic sealing liquid FUJI XEROX CO., LTD. (JP) 2006-08-30 EP disclosed
EP-1676894-A1 Ink, ink set, processing solution, recording method, recording medium, ink tank, and recording device FUJI XEROX CO., LTD. (JP) 2006-07-05 EP disclosed
US-20060139426-A1 Ink, ink set, processing solution, recording method, recording medium, ink tank, and recording device FUJI XEROX CO., LTD. 2006-06-29 US disclosed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY DNMT1, DNASE1, DNPEP KCNH2 484/4885EEF2K 1702/4885EEF2 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.